SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

MAR003

LSTA·LISATA THERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Unknown; MAR003 is preclinical and no clinical trial enrollment has been publicly identified. If it follows the siRNA development path, it would likely be several years from potential commercialization.
Why 2/10
No hard dated catalyst is scheduled for MAR003 in the next ~12 months; it is a preclinical IPR&D asset with no publicly identified clinical trial enrollment, PDUFA date, or regulatory milestone. The score is limited to 2 because the drug is preclinical with no upcoming binary event, even though it is part of the company's pipeline narrative.
Actionable Insight NEUTRAL

MAR003 is too early-stage (preclinical) to drive LSTA's near-term share price. Investors should instead focus on the November 30, 2026 annual meeting vote for Series C conversion (which unlocks the ~350M share resale registration overhang) and on upcoming clinical catalysts for MAR001 (Phase 2b hypertriglyceridemia data presented at AHA Nov 6-9, 2026) and MAR002 (Phase 2 acromegaly trial enrollment).

Price Chart

Loading chart...

Executive Summary

MAR003 is a preclinical-stage cardioendocrine drug candidate from Marea Therapeutics, which was acquired by Lisata Therapeutics (LSTA) in a September 2026 reverse merger backed by a $225 million private placement. Very little public information exists about MAR003's specific mechanism or target, though it is believed to be part of Marea's siRNA platform. It was valued as an in-process research and development (IPR&D) asset in the acquisition's purchase price allocation, sharing a $292.9M allocation with the more advanced MAR001/005 and MAR002 programs. MAR003 has no clinical trials registered, no disclosed development timeline, and no imminent catalysts. For LSTA investors, MAR003 is a distant future story; the company's near-term value drivers are the MAR001 Phase 2b data (recently reported positive at AHA 2026), the MAR002 Phase 2 acromegaly trial, and the high-stakes November 30 shareholder vote on Series C preferred stock conversion.

How It Works

MAR003 is a preclinical cardioendocrine drug candidate within Marea Therapeutics' (now a Lisata subsidiary) pipeline. Based on context from company statements about an 'siRNA platform expanding,' it is likely an siRNA-based (gene-silencing) therapy targeting an undisclosed cardiometabolic disease pathway. No specific mechanism has been publicly disclosed as of November 2026.

Trial Status

MAR003 is a preclinical-stage candidate. No clinical trials have been registered on ClinicalTrials.gov and no specific mechanism or target has been publicly disclosed as of November 2026.

The Two-Sided Case

▲ Bull Case3
MAR003 is part of a $292.9M IPR&D allocation from the Marea acquisition, signaling the acquiring company (backed by a $225M PIPE from top healthcare investors) sees meaningful value in the preclinical pipeline.
Marea's siRNA platform (which MAR003 is likely part of) leverages human genetics for first-in-class cardioendocrine targets, a validated approach that has produced MAR001 (positive Phase 2b data) and MAR002 (promising Phase 1 data).
The combined company has a strong syndicate of healthcare-focused investors (RA Capital, Perceptive, Third Rock, venBio, Sofinnova, Forbion) that participated in the $225M PIPE, providing cash runway.
▼ Bear Case4
MAR003 is a preclinical/early-stage asset with no disclosed mechanism, no clinical data, and no identified catalyst timeline; it is likely years from entering clinical trials.
LSTA faces massive dilution risk: the S-3 shelf registers ~350M shares for resale, roughly 32x the current 10.8M float, creating severe overhang.
The company is a combined entity with no approved products, a ~$12M market cap, and pro forma net losses of ~$49.8M in just H1 2026 alone.
The November 30, 2026 shareholder vote on Series C conversion is a binary event; failure would trigger cash settlement obligations.

Upcoming Catalysts

  • November 30, 2026: Lisata annual meeting adjourned for shareholder vote on Series C preferred stock conversion (critical to unlocking the Marea/PIPE financing structure).
  • Late 2026/Early 2027: Potential next steps for MAR002 Phase 2 acromegaly trial enrollment updates.
  • No near-term catalysts identified for MAR003 specifically.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

LISATA THERAPEUTICS, INC. 8-K/A LSTA ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 morningstar.com3 sec.gov4 markets.financialcontent.com5 fiercebiotech.com6 sec.gov7 theglobeandmail.com